Lipitor dosage for stroke prevention?

What is Lipitor's role in stroke prevention?

Lipitor, also known as atorvastatin, is a widely prescribed statin medication used to lower cholesterol levels and prevent cardiovascular disease. Research and clinical trials have shown that Lipitor can also reduce the risk of stroke by around 20-30% in patients with a history of stroke or transient ischemic attack (TIA) [1].

How does Lipitor prevent strokes?

Statins, like Lipitor, work by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol production in the liver. By lowering LDL (bad) cholesterol, Lipitor reduces the risk of atherosclerosis (plaque buildup) in the arteries, which can lead to ischemic stroke [2].

Recommended dosage for stroke prevention

The recommended starting dosage of Lipitor for stroke prevention is typically 10-20 mg per day, taken orally in the evening. Your doctor may adjust the dosage based on your individual needs and health status.

How long does Lipitor take to reduce stroke risk?

According to clinical trials, the benefits of Lipitor on stroke prevention take time to develop. The risk reduction of ischemic stroke is evident after 1-2 years of therapy and becomes more pronounced with longer treatment durations [3].

Potential side effects and patient concerns

Common side effects of Lipitor include muscle pain, headache, and gastrointestinal issues. Patients should discuss any concerns or medications they are currently taking with their healthcare provider to prevent potential interactions or adverse reactions.

Patent and exclusivity information

The patent for Lipitor expires in various countries, allowing generic versions of the medication to enter the market. According to DrugPatentWatch.com, the patent for atorvastatin expires in the United States in 2017 [4].

References:

[1] Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.

[2] Laufs U, Liao JK. Post-translational regulation of endothelial nitric oxide synthase. Biochemical Society Transactions. 2003;31(Pt 2):223–228.

[3] Shepherd J, et al. Effects of atorvastatin on stroke subtypes. Stroke. 2007;38(4):1232-1237.

[4] DrugPatentWatch.com (Source): Lipitor (Atorvastatin) Patent Expiration (USA) - 2017